Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Solriamfetol Dose A · 2 trials · 1 indication
Attention Deficit/ Hyperactivity Disorder Rating Scale-5, Interview with Informant, Child Version (ADHD-RS-5)
| Arm | Type | Description |
|---|---|---|
| Solriamfetol Dose A | EXPERIMENTAL | Up to 6 weeks |
| Solriamfetol Dose B | EXPERIMENTAL | Up to 6 weeks |
| Placebo | PLACEBO_COMPARATOR | Up to 6 weeks |
| Name | Type | Description |
|---|---|---|
| Solriamfetol Dose A | DRUG | Solriamfetol capsules, taken once daily |
| Solriamfetol Dose B | DRUG | Solriamfetol capsules, taken once daily |
| Placebo | DRUG | Placebo capsules, taken once daily |
Inclusion Criteria: * Male or female, aged 6 to \<12 years. * Primary diagnosis of ADHD according to DSM-5 criteria. * Has parents/legal guardians provide written informed consent and has child provide written informed assent to participate in the study before the conduct of any study procedures. ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 1 | PHASE3 | SPN-812 |
Solriamfetol Dose A is an investigational small molecule being studied for the treatment of attention deficit hyperactivity disorder (ADHD). It is currently in Phase 3 clinical development, with trials enrolling children aged 6 years and older and adolescents aged 12 years and older in the United States.
Solriamfetol Dose A is being developed by Axsome Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AXSM. The company is conducting Phase 3 clinical trials to evaluate the efficacy and safety of this drug in patients with ADHD.
Solriamfetol Dose A is in Phase 3 clinical development for ADHD. It is an investigational drug that has not yet been approved by regulatory authorities. Two Phase 3 trials are currently recruiting participants to assess its efficacy and safety in children and adolescents with ADHD.
Solriamfetol Dose A is being evaluated in two Phase 3 clinical trials: NCT07717879, a study in children with ADHD aged 6 years and older, and NCT07717892, a study in adolescents with ADHD aged 12 years and older. Both trials are recruiting in the United States and are randomized, double-blind, and placebo-controlled.
Solriamfetol Dose A is a specific dose formulation of solriamfetol, a small molecule being studied for ADHD. While solriamfetol is the active pharmaceutical ingredient, Solriamfetol Dose A refers to the particular dose being evaluated in the Phase 3 trials for this indication.